fc188 register

CINCINNATI , Nov. 22, 2024 /PRNewswire/ -- The Kroger Co. (NYSE: KR) today announced that Stuart Aitken is stepping down as senior vice president, chief merchandising and marketing officer, to pursue other professional opportunities. Aitken will remain in his role at Kroger through December 31, 2024 . Mary Ellen Adcock , Kroger's senior vice president of operations, will succeed him as chief merchandising and marketing officer. " Mary Ellen is a respected leader both within Kroger and our industry," said Rodney McMullen , Kroger's chairman and CEO. "Her deep strategic experience in her past 25 years with Kroger in roles of increasing responsibility will continue to drive value for customers and growth for our business and associates." Continuing in their current roles as leaders of the company's operations are senior vice presidents of retail operations Valarie Jabbar and Kenny Kimball , who oversee Kroger operating divisions, and group vice president of retail operations Paula Kash , who leads enterprise retail operations, which includes asset protection, corporate food technology and e-commerce operations. They will now report to McMullen. "On behalf of the Kroger Board and management team, I want to thank Stuart for his work to evolve Kroger's brand while bringing exciting, innovating products to our shelves," said McMullen. "He played an instrumental role in overseeing dunnhumby's integration and establishing 84.51o. We wish Stuart and his family all the best as they embark on a new chapter." About Mary Ellen Adcock Adcock served as Kroger's senior vice president of operations since 2019. In this role, she leads strategic operations for the company's more than 2,700 stores across 35 states supporting more than 416,000 associates and serving 11 million customers every day. Adcock oversees customer experience, associate experience, asset protection, process change and productivity improvement initiatives and is responsible for maintaining the highest food safety and regulatory standards. As senior vice president of operations, Adcock has delivered more than $1 billion in annual operations savings for six consecutive years. This strategic focus on efficiency improvements provided Kroger the ability to reinvest those savings to consistently lower prices for customers and increase wages for associates. Adcock achieved this efficiency goal while also improving the customer and associate experience by developing Kroger's Full, Fresh & Friendly: Every Customer Every Time program. Adcock also played a lead role in operationalizing Zero Hunger | Zero Waste, Kroger's commitment to end hunger in the communities it serves and eliminate waste as a company. She led the organization in achieving 100% store participation in the company's surplus food rescue program for the first time. Adcock joined Kroger in 1999 in the company's manufacturing division, where she held a variety of leadership positions. In 2009, she was promoted to vice president of deli/bakery manufacturing, and in 2012, Adcock became vice president of natural foods. In 2014, she led merchandising and operations for the Columbus division. Adcock was promoted to group vice president of retail operations in 2016 and named as senior vice president of retail operations in 2019. In 2022, Adcock was a Top Women in Grocery Trailblazer. About Kroger At The Kroger Co. (NYSE: KR), we are dedicated to our Purpose: To Feed the Human SpiritTM. We are, across our family of companies nearly 420,000 associates who serve over 11 million customers daily through a seamless digital shopping experience and retail food stores under a variety of banner names , serving America through food inspiration and uplift, and creating #ZeroHungerZeroWaste communities. To learn more about us, visit our newsroom and investor relations site. View original content to download multimedia: https://www.prnewswire.com/news-releases/kroger-announces-chief-merchandising-and-marketing-officer-succession-302314616.html SOURCE The Kroger Co.HOUSTON (AP) — Will Levis and the Tennessee Titans were far from perfect Sunday. But they did just enough to outlast the mistake-prone Houston Texans and get their first AFC South win of the season. Levis threw for 278 yards and his 70-yard touchdown pass to Chig Okonkwo put Tennessee on top in the fourth quarter and the Titans held on for the 32-27 victory. “The coolest thing about this game was just the way our team fought,” coach Brian Callahan said. “It was a back-and-forth game. Our guys did a good job of not flinching and keeping the blinders on. We’ve been in games like this before, and we haven’t been able to make a play, but this week, we made a play.” Okonkwo grabbed a short pass and rumbled for the touchdown to put the Titans (3-8) up 30-27 with 91⁄2 minutes remaining. Safety Eric Murray missed a tackle that would have stopped him near midfield. The Texans (7-5) had a chance to tie it with less than two minutes remaining, but Ka’imi Fairbairn’s 28-yard field-goal attempt sailed wide left. He fell to the ground after the miss before getting up and slamming his helmet on the field. Callahan held both hands in the air and smiled after watching the miss that allowed his team to win on a day it had three turnovers. The Texans forced a three-and-out, but couldn’t move the ball after that and Harold Landry sacked C.J. Stroud in the end zone for a safety to make it 32-27 and allow Tennessee to snap a two-game skid. Stroud threw for 247 yards and two touchdowns, but also threw two interceptions as the AFC South-leading Texans lost for the third time in four games. Stroud has thrown five interceptions combined in the past three games to give him more interceptions in 12 games this season (nine) than he had in 15 games as a rookie last season (five). “It’s no secret that I haven’t been playing well... I’ve got to be harder on myself,” he said. “I’m not going to hold my head down. I know I can be a great player, but I’ve got to make better plays.” Jimmie Ward had a 65-yard interception return for a touchdown in the third quarter and the Texans tied a franchise record with eight sacks. Danielle Hunter led the group with a season-high three sacks and Will Anderson Jr. added two in his return after missing two games with an ankle injury. But the offense sputtered for most of the game as Joe Mixon was held to 22 yards on 14 carries. “Just a disappointing loss for us,” coach DeMeco Ryans said. “We didn’t do anything well enough to win this game. Out of all the positives that we did have, there were way too many negatives.” It was Tennessee's first win of the season in a game that Levis both started and finished. The second-year player missed three games this year with a sprained AC joint in his throwing shoulder. “I’m really proud of Will,” Callahan said. “He’s done a lot of things to get himself back in the right place, mentally and physically. It was a really good performance.” Levis knows he can be better, but was happy to leave Houston with a victory in this difficult season. “It feels awesome,” he said. “A lot of people have been working really hard to get a win like this. I’m just happy for the organization, top down.” Tennessee extended the lead to 23-17 on a 51-yard field goal by Nick Folk with nine minutes left in the third. Stroud threw his second interception with about 90 seconds left in the third quarter but Ward’s touchdown came three plays later to put the Texans on top 24-23. The Titans fumbled a punt early in the fourth quarter and Houston recovered it. A 54-yard field goal by Fairbairn extended the lead to 27-23 with about 10 minutes to go. Dameon Pierce returned the opening kickoff 80 yards to get the Texans in the red zone. Houston cashed in on the next play when Stroud found rookie Cade Stover on a 19-yard pass for his first touchdown reception. The Titans trailed by four after a field goal by Folk when Nick Westbrook-Ikhine got in front of the defense and was wide open for a 38-yard TD catch that made it 10-7 late in the first quarter. Tennessee extended the lead to 17-7 when Tony Pollard ran 10 yards for a touchdown with about 11 minutes left in the second. Pollard finished with 119 yards and a touchdown. Nico Collins scored on a 5-yard reception with about six minutes left in the second. Levis levis lost a fumble with about 3 1/2 minutes left and the Texans added a 28-yard field goal to tie it at 17-17. Houston forced a punt after that, but rookie Jarvis Brownlee Jr. got his first career interception two plays later to give Tennessee the ball back. Folk’s 56-yard field goal, which tied his career long, put the Titans up 20-17 at halftime. The Titans were without cornerback L’Jarius Sneed, after he was placed on injured reserve with a quadriceps injury, and safety Amani Hooker, who was added to the injury report Sunday morning with an illness. Callahan said Hooker was vomiting “every time he stood up” Sunday. ... Houston S Jalen Pitre injured his shoulder in the second quarter and didn’t return. ... CB Ka’dar Hollman left in the fourth quarter with a knee injury. Titans: Visit the Commanders next Sunday. Texans: Visit Jacksonville next Sunday. AP NFL: https://apnews.com/hub/nfl

Residents take to the water to escape massive Tondo fireBlame it on the food and drink?

The Washington Commanders (7-5) experienced what is easily the toughest loss of the season and also one of the scariest moments at the end of the game when veteran running back Austin Ekeler suffered a hard hit that left him motionless on the ground. Ekeler returned a kickoff and was trying to get the offense in good field position for a final Hail Mary attempt when he was decked by Dallas Cowboys players Nick Vigil and Dwight Clark. He immediately fell to the turf and didn't move. Several teammates instantly waved to the sideline for trainers to come out and check on him. Fortunately, he eventually walked off the field. Very scary scene here to close the Commanders-Cowboys game. Austin Ekeler down on the field. pic.twitter.com/VPMo32shBQ Commanders head coach Dan Quinn updated Ekeler's status after the game. He suffered a concussion, which is the second one he's suffered this year. "I just had a chance to visit with him now. He'll do more tests, tonight, but it was a concussion." As a result, the team decided to send him to the hospital as a precaution. Ekeler finished the game with 22-yards on nine carries and two-yards on two receptions. It's more unfortunate injury news regarding the running back room, as the team also lost top running back Brian Robinson Jr. to a sprained ankle earlier in the game. Out of an abundance of caution Austin Ekeler is headed to the hospital for further testing, per Commanders spokesperson This article first appeared on A to Z Sports and was syndicated with permission.Spotify Wrapped 2024 campaign debuts alongside Pop-Up Rave in Parramatta

No. 24 UCLA is seeking its eighth straight win on Saturday against an Arizona team that is trying to right the ship after dropping four of its last six games. The game is being played in Phoenix, billed as part of the Hall of Fame Series. It's the first meeting between the storied ex-Pac-12 rivals since the conference's collapse last year and will be the first time the teams have met in a nonconference matchup since 1977. UCLA (8-1) is off to a surprisingly hot start after a nightmarish last season. The Bruins have won seven in a row after falling to New Mexico on Nov. 8. They're coming directly off a 73-71 victory over No. 12 Oregon on Sunday on a game-winning 3-pointer by Dylan Andrews with 0.3 seconds remaining. Eric Dailey Jr. led the way with 19 points on 7-of-8 shooting. The Bruins sit at 2-0 in conference play in their first season as a member of the Big Ten. "My analysis early of the Big Ten is that it's so deep," UCLA coach Mick Cronin said. "I know it probably always was that way, but now it's deeper. You've just got to get better. "I also coach at UCLA where we get the most titles and (have been to) the second-most finals. I didn't come to UCLA to win regular-season games. For us, it's about progression and getting better. "We were able to win (against Oregon) but I thought we got a lot better. We came together. We got more cohesive. The guys played with confidence." Tyler Bilodeau leads UCLA in scoring and rebounding, averaging 13.3 points and 5.9 rebounds per game. Bilodeau played his first two collegiate seasons at Oregon State, although his maiden voyage at UCLA is only his second season as a regular starter. Dailey, a transfer from Oklahoma State, doesn't trail too far behind in either category, averaging 12.3 points and 5.2 rebounds per game. USC transfer Kobe Johnson leads the Bruins with 3.2 assists while also tallying 7.3 points and 5.1 rebounds per game. The Wildcats (4-4) are in the midst of a dreadful start, needing a 102-66 win over Southern Utah to nurse themselves back to .500. Before that, Arizona was just one for its last five. The Wildcats are winless against fellow power-conference opponents, suffering double-digit losses to Wisconsin and Duke. Arizona also absorbed a five-point loss to Oklahoma and a seven-point overtime loss to West Virginia at the Battle 4 Atlantis. "Great programs are going to stumble once in a while," Arizona coach Tommy Lloyd said. "The response is the key. Learning from it and coming back stronger is the objective and that's the challenge. We obviously have been challenged early in the season. "(The emphasis needs to be on) Arizona basketball, because here's the deal: UCLA is a good program. If we go in and all we're worried about is UCLA and we assume that we're going to show up and play well, we're going to get our ass kicked." The Wildcats are led by Caleb Love, who returned for a second season at Arizona and a fifth in college overall after he played his first three seasons at North Carolina. Love is averaging 14.1 points per game on 37.2 percent shooting, down from 18 points per game a season ago. Aside from Love, Arizona has four more players averaging in double figures for the season: Jaden Bradley (12.0 ppg), Trey Townsend (11.3), KJ Lewis (10.3) and Anthony Dell'Orso (10.0). --Field Level Media

WEST PALM BEACH, Fla. — Donald Trump hosted Apple CEO Tim Cook for a Friday evening dinner at the president-elect's Mar-a-Lago resort, according to a person familiar with the matter who was not authorized to comment publicly. Cook is the latest in a string of big tech leaders — including OpenAI's Sam Altman, Meta's Mark Zuckerberg and Amazon's Jeff Bezos — who have sought to improve their standing with the incoming president after choppy relations with Trump during his first term. Trump has said he has spoken with Cook about the company's long-running tax battles with the European Union. The meeting comes less than two months after Trump said he spoke to Cook by phone, and soon after Apple lost its last appeal in a dispute with the EU over 13 billion euros ($14.34 billion) in back taxes to Ireland. “He said the European Union has just fined us $15 billion," Trump recalled of his conversation with Cook, in an October interview with podcaster Patrick Bet-David. "Then on top of that they got fined by the European Union another $2 billion." Get the latest breaking news as it happens. By clicking Sign up, you agree to our privacy policy . The decision by the EU top court was the finale to a dispute that centered on sweetheart deals that Dublin was offering to attract multinational businesses with minimal taxes across the 27-nation bloc. The European Commission in 2016 ruled that Ireland granted Apple unlawful aid that Ireland was required to recover. Trump's transition team and Apple did not immediately respond to a request for comment about his dinner with Cook. President-elect Donald Trump listens during an America First Policy Institute gala at his Mar-a-Lago estate, Thursday, Nov. 14, 2024, in Palm Beach, Fla. Credit: AP/Alex Brandon OpenAI CEO Altman is planning to make a $1 million personal donation to Trump’s inauguration fund, the company confirmed Friday. Amazon and Meta, the parent company of Facebook and Instagram, confirmed this week they had each donated $1 million to Trump’s inaugural fund. During his first term, Trump criticized Amazon and railed against the political coverage at The Washington Post, which Bezos owns. Meanwhile, Bezos had criticized some of Trump’s past rhetoric. In 2019, Amazon also argued in a court case that Trump’s bias against the company harmed its chances of winning a $10 billion Pentagon contract. More recently, Bezos has struck a more conciliatory tone. Last week, he said at The New York Times’ DealBook Summit in New York that he was “optimistic” about Trump’s second term while also endorsing president-elect’s plans to cut regulations. The donation from Meta came just weeks after Meta CEO Zuckerberg met with Trump privately at Mar-a-Lago. Apple CEO Tim Cook leaves 10 Downing Street after a meeting with Britain's Prime Minister Keir Starmer in London, Wednesday, Dec. 11, 2024. Credit: AP/Alberto Pezzali During the 2024 campaign, Zuckerberg did not endorse a candidate for president, but voiced a more positive stance toward Trump. Earlier this year, he praised Trump’s response to his first assassination attempt.Join our newsletter to get the latest military space news every Tuesday by veteran defense journalist Sandra Erwin. WASHINGTON — Umbra Space secured a contract extension with the National Reconnaissance Office, the company announced Dec. 4. The California-based startup, which specializes in synthetic aperture radar (SAR) satellite technology, has been working with the agency since 2022 under the Strategic Commercial Enhancements initiative. The extension offers the company continued opportunities to demonstrate its technology and refine its offerings to meet government needs, said Joe Morrison, Umbra’s vice president of remote sensing. The financial terms of the contract were not disclosed. Unlike traditional optical imaging satellites, SAR can penetrate clouds and capture high-resolution images in all weather conditions, day or night. This makes the technology valuable for applications such as environmental monitoring, disaster response, maritime surveillance and intelligence gathering. Umbra currently operates five spacecraft, with more in production. The company is positioning itself in the government and commercial markets, Morrison noted, developing satellites for its own constellation and for international government clients. Umbra is one of several SAR imaging companies the NRO selected in 2022 for study contracts. Companies’ performance under these cooperative agreements positions them to compete in an upcoming “ Commercial Radar Layer ” program, a multi-year initiative modeled after the agency’s Electro Optical Commercial Layer program, which awarded contracts to three firms in 2022. The NRO, a U.S. intelligence agency responsible for designing, building and operating reconnaissance satellites, has a Commercial Systems Program Office that plays a pivotal role in integrating technology from private industry into national security operations. “The beautiful thing about the NRO is that they’re incredibly meritocratic,” Morrison said. “They don’t reward bluster or marketing. They reward performance.” Morrison credited the NRO’s expertise with helping commercial firms navigate the complex demands of government markets. “If you can go in humbly and ask, ‘What do you need?’ they will tell you exactly what they need to see.” Under the NRO’s Strategic Commercial Enhancements initiative, Umbra is also working with the agency to provide radio frequency (RF) data collected by its SAR satellites that can be used to locate and track electronic emissions.

Saints say Taysom Hill 'likely' has a season-ending knee injuryHICKSVILLE, N.Y. , Dec. 13, 2024 /PRNewswire/ -- Flagstar Financial, Inc. (NYSE: FLG) ( the "Company"), today announced the appointment of Lee Smith as Senior Executive Vice President and Chief Financial Officer (CFO), effective December 27, 2024 . The appointment follows the decision of current CFO Craig Gifford to step down to reengage in personal endeavors outside of the banking industry. Gifford will remain with the Bank through March 31, 2025 , and work closely with Smith during the transition period, ensuring a seamless hand-over and continued support for the Bank's ongoing initiatives. "For more than a decade, Lee has been an instrumental member of Flagstar's executive team. He is a proven leader with a strong track record, has the requisite experience and expertise, and possesses deep knowledge of the Company. The Board of Directors and I have full faith and confidence in Lee to continue to help guide the Company in this financial leadership position," said Joseph M. Otting , Chairman, President, and CEO. Smith joined legacy Flagstar Bancorp, Inc. in 2013 as Chief Operating Officer and his transition to CFO comes after serving on Flagstar's executive management team for more than a decade, most recently as President of Mortgage. He has an extensive background in accounting, finance, mortgage, private equity, and operations, spanning more than 25 years. His experience in managing large-scale transactions, optimizing financials and operations, and working with regulators demonstrates a strong ability to drive financial performance, ensure compliance, and lead financial operations. Additionally, his leadership in M&A deals, capital markets, and financial management positions him well to oversee financial strategies, risk mitigation, and operational efficiency at a senior financial level. His prior roles include Partner at Matlin Patterson Global Advisers LLC, a private investment firm. He is also a member of the Institute of Chartered Accountants in England and Wales (ICAEW) since 1998 and has a BSc in Economics and Accountancy from Loughborough University in England . Otting added, "I want to express our sincere appreciation to Craig for his impactful contributions over the past year. His leadership during this time has been invaluable, and we wish him all the best. As all of our stakeholders know, we have been working relentlessly to elevate Flagstar to new heights. I also recognize the personal sacrifices and time commitment required away from our personal lives for this journey. Given the substantial progress we've made as a Company, I am comfortable that this is a good time for this transition, and I am confident the momentum we've gained will only strengthen as we move forward." About Flagstar Financial, Inc. Flagstar Financial, Inc. is the parent company of Flagstar Bank, N.A., one of the largest regional banks in the country. The Company is headquartered in Hicksville, New York . At September 30, 2024, the Company had $114.4 billion of assets, $73.0 billion of loans, deposits of $83 .0 billion, and total stockholders' equity of $8 .6 billion. Flagstar Bank, N.A. operates over 400 branches, including a significant presence in the Northeast and Midwest and locations in high growth markets in the Southeast and West Coast. In addition, the Bank has approximately 80 private banking teams located in over 10 cities in the metropolitan New York City region and on the West Coast, which serve the needs of high-net worth individuals and their businesses. Cautionary Statements Regarding Forward-Looking Statements This release may include forward‐looking statements by the Company and our authorized officers pertaining to such matters as our goals, beliefs, intentions, and expectations regarding (a) revenues, earnings, loan production, asset quality, liquidity position, capital levels, risk analysis, divestitures, acquisitions, and other material transactions, among other matters; (b) the future costs and benefits of the actions we may take; (c) our assessments of credit risk and probable losses on loans and associated allowances and reserves; (d) our assessments of interest rate and other market risks; (e) our ability to execute on our strategic plan, including the sufficiency of our internal resources, procedures and systems; (f) our ability to attract, incentivize, and retain key personnel and the roles of key personnel; (g) our ability to achieve our financial and other strategic goals, including those related to our merger with Flagstar Bancorp, Inc., which was completed on December 1, 2022, our acquisition of substantial portions of the former Signature Bank through an FDIC-assisted transaction, and our ability to fully and timely implement the risk management programs institutions greater than $100 billion in assets must maintain; (h) the effect on our capital ratios of the approval of certain proposals approved by our shareholders during our 2024 annual meeting of shareholders; (i) the conversion or exchange of shares of the Company's preferred stock; (j) the payment of dividends on shares of the Company's capital stock, including adjustments to the amount of dividends payable on shares of the Company's preferred stock; (k) the availability of equity and dilution of existing equity holders associated with amendments to the 2020 Omnibus Incentive Plan; (l) the effects of the reverse stock split; and (m) transactions relating to the sale of our mortgage business and mortgage warehouse business. Forward‐looking statements are typically identified by such words as "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "should," "confident," and other similar words and expressions, and are subject to numerous assumptions, risks, and uncertainties, which change over time. Additionally, forward‐looking statements speak only as of the date they are made; the Company does not assume any duty, and does not undertake, to update our forward‐looking statements. Furthermore, because forward‐looking statements are subject to assumptions and uncertainties, actual results or future events could differ, possibly materially, from those anticipated in our statements, and our future performance could differ materially from our historical results. Our forward‐looking statements are subject to, among others, the following principal risks and uncertainties: general economic conditions and trends, either nationally or locally; conditions in the securities, credit and financial markets; changes in interest rates; changes in deposit flows, and in the demand for deposit, loan, and investment products and other financial services; changes in real estate values; changes in the quality or composition of our loan or investment portfolios, including associated allowances and reserves; changes in future allowance for credit losses, including changes required under relevant accounting and regulatory requirements; the ability to pay future dividends; changes in our capital management and balance sheet strategies and our ability to successfully implement such strategies; recent turnover in our Board of Directors and our executive management team; changes in our strategic plan, including changes in our internal resources, procedures and systems, and our ability to successfully implement such plan; changes in competitive pressures among financial institutions or from non‐financial institutions; changes in legislation, regulations, and policies; the imposition of restrictions on our operations by bank regulators; the outcome of pending or threatened litigation, or of investigations or any other matters before regulatory agencies, whether currently existing or commencing in the future; the success of our blockchain and fintech activities, investments and strategic partnerships; the restructuring of our mortgage business; our ability to recognize anticipated expense reductions and enhanced efficiencies with respect to our recently announced strategic workforce reduction; the impact of failures or disruptions in or breaches of the Company's operational or security systems, data or infrastructure, or those of third parties, including as a result of cyberattacks or campaigns; the impact of natural disasters, extreme weather events, military conflict (including the Russia / Ukraine conflict, the conflict in Israel and surrounding areas, the possible expansion of such conflicts and potential geopolitical consequences), terrorism or other geopolitical events; and a variety of other matters which, by their nature, are subject to significant uncertainties and/or are beyond our control. Our forward-looking statements are also subject to the following principal risks and uncertainties with respect to our merger with Flagstar Bancorp, which was completed on December 1, 2022 , and our acquisition of substantial portions of the former Signature Bank through an FDIC-assisted transaction: the possibility that the anticipated benefits of the transactions will not be realized when expected or at all; the possibility of increased legal and compliance costs, including with respect to any litigation or regulatory actions related to the business practices of acquired companies or the combined business; diversion of management's attention from ongoing business operations and opportunities; the possibility that the Company may be unable to achieve expected synergies and operating efficiencies in or as a result of the transactions within the expected timeframes or at all; and revenues following the transactions may be lower than expected. Additionally, there can be no assurance that the Community Benefits Agreement entered into with NCRC, which was contingent upon the closing of the Company's merger with Flagstar Bancorp, Inc., will achieve the results or outcome originally expected or anticipated by us as a result of changes to our business strategy, performance of the U.S. economy, or changes to the laws and regulations affecting us, our customers, communities we serve, and the U.S. economy (including, but not limited to, tax laws and regulations). More information regarding some of these factors is provided in the Risk Factors section of our Annual Report on Form 10 ‐ K/A for the year ended December 31, 2023, Quarterly Report on Forms 10-Q for the quarters ended March 31, 2024 , June 30, 2024 , and September 30, 2024 , and in other SEC reports we file. Our forward ‐ looking statements may also be subject to other risks and uncertainties, including those we may discuss in this news release, on our conference call, during investor presentations, or in our SEC filings, which are accessible on our website and at the SEC's website, www.sec.gov . Investor Contact: Salvatore J. DiMartino (516) 683-4286 Media Contact: Steven Bodakowski (248) 312-5872 View original content to download multimedia: https://www.prnewswire.com/news-releases/flagstar-financial-inc-names-lee-smith-as-chief-financial-officer-302331680.html SOURCE Flagstar Financial, Inc.

Caprock Group LLC increased its stake in Aptiv PLC ( NYSE:APTV – Free Report ) by 46.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,423 shares of the auto parts company’s stock after buying an additional 1,708 shares during the quarter. Caprock Group LLC’s holdings in Aptiv were worth $391,000 as of its most recent filing with the SEC. A number of other hedge funds have also recently bought and sold shares of APTV. EdgePoint Investment Group Inc. acquired a new stake in Aptiv during the 1st quarter valued at approximately $335,426,000. Massachusetts Financial Services Co. MA grew its stake in Aptiv by 15.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 12,861,135 shares of the auto parts company’s stock valued at $905,681,000 after purchasing an additional 1,764,844 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Aptiv by 13.7% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 7,515,074 shares of the auto parts company’s stock valued at $529,212,000 after purchasing an additional 905,431 shares in the last quarter. Mizuho Securities USA LLC grew its stake in Aptiv by 3,679.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 792,581 shares of the auto parts company’s stock valued at $57,074,000 after purchasing an additional 771,608 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Aptiv by 1,368.6% during the 3rd quarter. SG Americas Securities LLC now owns 414,273 shares of the auto parts company’s stock worth $29,832,000 after buying an additional 386,064 shares during the last quarter. Institutional investors and hedge funds own 94.21% of the company’s stock. Wall Street Analyst Weigh In A number of research analysts have commented on APTV shares. Deutsche Bank Aktiengesellschaft reduced their target price on Aptiv from $76.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, November 1st. Oppenheimer reduced their target price on Aptiv from $147.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Bank of America reduced their target price on Aptiv from $105.00 to $102.00 and set a “buy” rating on the stock in a report on Monday, October 14th. Morgan Stanley reduced their target price on Aptiv from $68.00 to $60.00 and set an “underweight” rating on the stock in a report on Thursday, November 14th. Finally, Barclays reduced their target price on Aptiv from $100.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.29. Aptiv Stock Up 1.9 % Shares of APTV stock opened at $54.38 on Friday. Aptiv PLC has a 1 year low of $51.47 and a 1 year high of $91.66. The stock has a market cap of $12.78 billion, a PE ratio of 6.07, a price-to-earnings-growth ratio of 0.48 and a beta of 1.81. The business’s fifty day moving average is $65.09 and its 200-day moving average is $70.43. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.06 and a current ratio of 1.50. Aptiv ( NYSE:APTV – Get Free Report ) last issued its quarterly earnings results on Thursday, October 31st. The auto parts company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.15. Aptiv had a return on equity of 14.51% and a net margin of 12.29%. The company had revenue of $4.85 billion for the quarter, compared to analysts’ expectations of $5.10 billion. During the same period last year, the firm earned $1.30 EPS. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities analysts expect that Aptiv PLC will post 6.15 earnings per share for the current fiscal year. About Aptiv ( Free Report ) Aptiv PLC engages in design, manufacture, and sale of vehicle components in North America, Europe, Middle East, Africa, the Asia Pacific, South America, and internationally. The company provides electrical, electronic, and safety technology solutions to the automotive and commercial vehicle markets. It operates through two segments, Signal and Power Solutions, and Advanced Safety and User Experience. Featured Stories Receive News & Ratings for Aptiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptiv and related companies with MarketBeat.com's FREE daily email newsletter .

- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M - Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025 - Entered strategic research collaboration with BioMarin valued at over $370M CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “The third quarter of 2024 has been transformational for CAMP4, highlighted by our successful IPO and continued strong progress with our lead program, CMP-CPS-001, which received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, underscoring its potential as a novel therapeutic candidate for the treatment of urea cycle disorders,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “We also partnered with BioMarin to identify novel therapeutics targeting regRNAs associated with genetic diseases, validating the potential of our RNA Actuating Platform and reinforcing our commitment to advance cutting-edge solutions for patients in need.” Mr. Mandel-Brehm continued, “We continue to advance our CMP-CPS-001 program through the Phase 1 trial, and we anticipate reporting SAD safety data in the first quarter of 2025 followed by multiple ascending dose (MAD) biomarker efficacy data in the second half of 2025, that may enable a registrational Phase 2/3 study. With the proceeds from our IPO, we are well positioned to support continued clinical and preclinical development of our ongoing programs.” Recent Corporate Highlights: Third Quarter 2024 Financial Results CAMP4 ended the third quarter with $2.5 million in cash and cash equivalents. On a pro forma basis, considering the $82.1M IPO proceeds, the company is well positioned to support continued growth and the development of its ongoing programs. Research and Development (R&D) expenses were $9.7 million for the third quarter of 2024 compared to $9.8 million for the third quarter of 2023. The decrease was mainly due to a modest reduction in workforce-related expense, offset in part by an increase in lab operation expense and preclinical and clinical consulting fees. General and administrative (G&A) expenses were $3.8 million for the quarter ended September 30, 2024, compared to $2.9 million for the quarter ended September 30, 2023. The increase in G&A expenses was primarily due to an increase in stock-based compensation expense and higher patent-related expenses vs. prior period. Net loss was $13.5 million for the third quarter 2024, compared to $11.7 million for the same period in 2023. About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP PlatformTM enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X . Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting SAD and MAD data from and seeking regulatory approval for the CMP-CPS-001 trial; its growth strategy; and cash balance guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations: Sandya von der Weid LifeSci Advisors svonderweid@lifesciadvisors.com Media: Jason Braco, Ph.D. LifeSci Communications jbraco@lifescicomms.com (1) Working capital is defined as total current assets less total current liabilities. See our condensed consolidated financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the period ended September 30, 2024 for further details regarding our current assets and current liabilities.FLAGSTAR FINANCIAL, INC. APPOINTS BRIAN CALLANAN TO BOARD OF DIRECTORS